The BTS reunion arithmetic lands on HYBE's balance sheet before it reaches any arena. All seven members cleared military service across a staggered discharge schedule that HYBE disclosed to KOSPI investors as a material risk starting in 2022, with the final members completing service in early 2026 and opening the first full touring window in Q3 2026. Industry booking agents in Seoul and New York have been pricing the world tour since Q4 2025, the trade consensus circulating around 12 stadium dates in North America and 8 in Japan, with a Southeast Asia leg that routes through Bangkok and Singapore. Hong Kong is not on the routing. The Coliseum is the wrong room.

HYBE built its enlistment bridge (Weverse platform licensing, catalogue streaming, merchandise volume from the 2022 Busan concert film) to sustain revenue through a three-year touring gap, and what the reunion tour must deliver now is not an emotional reset but the stadium MG floor that justifies the production overhead on HYBE's live-business line. The 2020 Korea Exchange IPO prospectus disclosed that artist royalty arrangements at Big Hit were structured at the subsidiary level, not the act level, meaning the reunion is at minimum seven simultaneous negotiations against the same post-2018 HYBE label override clause. A woman at Exit B of Hung Hom MTR was sorting Seoul versus Singapore ticket drops on her phone last Wednesday, with the focused urgency of someone who has accepted she will not get Seoul. Read the October 2020 prospectus.

The capital priced a lifespan drug. SELECT enrolled a cardiovascular trial. SELECT (NCT03574597, Novo Nordisk funded, n=17,604, median follow-up 33.8 months) enrolled adults with established cardiovascular disease, BMI of 27 or above, and no prior type 2 diabetes; its primary endpoint was major adverse cardiovascular events. The result, published in the NEJM in November 2023, was a 20% relative risk reduction in MACE. The family-office GLP-1 position is pricing the same molecule against a different primary endpoint, in a different population, on a mechanism the trial was not designed to test. The SELECT population and the longevity-consumer population share a drug. They do not share a hypothesis.

The regulatory architecture makes the gap precise. Neither FDA's Center for Drug Evaluation and Research nor NMPA's Center for Drug Evaluation has qualified a biological age surrogate as a primary endpoint in a drug approval application. TGA's Advisory Committee on Medicines has reviewed semaglutide and tirzepatide submissions on metabolic and cardiovascular grounds exclusively. The only active trial using aging itself as the indication is TAME, studying metformin under a composite endpoint of incident age-related diseases and all-cause mortality, n=3,000 target enrolment, funded by the American Federation for Aging Research. No GLP-1 trial matches that design. The position runs on a bet that cardiovascular event reduction maps to lifespan extension. CDER has not confirmed that mapping, and the Biomarker Qualification Program's list of accepted surrogate endpoints for aging currently has zero entries.